Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results. See why I rate IMUX ...

Looking at Immunic, Inc.'s ( NASDAQ:IMUX ) insider transactions over the last year, we can see that insiders were ...

Wolfe Research analyst Andrew Rosivach assumed coverage of Innovative Industrial Properties (IIPR) with an Outperform rating and $57 price ...